ImmunityBio Faces Regulatory Scrutiny Amid Strong Commercial Performance

Investors in biotechnology firm ImmunityBio are navigating a landscape of stark contrasts. The company’s commercial prospects appear increasingly bright, driven by its bladder cancer therapy Anktiva. However, this optimism is tempered by significant regulatory challenges, as a recent enforcement action from the U.S. Food and Drug Administration (FDA) has triggered a sharp decline in its share price and attracted the attention of class-action law firms.

Operational Momentum and Clinical Progress

From a business and clinical development perspective, ImmunityBio’s trajectory is notably positive. The commercial launch of Anktiva has generated substantial demand, leading to a dramatic revenue increase. For the full year 2025, net sales surged by approximately 700 percent to $113 million. The company is also well-capitalized to support its ongoing commercialization efforts, holding liquid assets of nearly $243 million. Anktiva is now approved for use in 33 countries.

On the research front, the clinical pipeline achieved a significant milestone on March 26. An interim analysis of the Phase 2b QUILT-2.005 study, investigating Anktiva for early-stage bladder cancer, demonstrated an improved response rate of 84 percent compared to 52 percent in the control group. Based on these results, the company plans to submit a supplemental marketing application to the FDA in the fourth quarter of 2026. A separate application for a specific tumor type was already filed with the agency in early March.

Should investors sell immediately? Or is it worth buying ImmunityBio?

FDA Warning Letter Sparks Legal and Market Turmoil

This robust operational picture is complicated by a serious regulatory dispute. The current volatility stems from an official warning letter the FDA sent to CEO Richard Adcock. The agency alleges that ImmunityBio engaged in the misleading promotion of Anktiva in television advertisements and podcasts. A particularly contentious detail is that the company had previously received two similar admonitions but apparently failed to adjust its promotional strategy sufficiently.

When this news became public last week, the market reacted severely. The share price fell 21 percent to $7.42. In the aftermath, several law firms are now assembling a class-action lawsuit, citing potential violations of securities law. Investors who purchased securities during the relevant period have until May 26 to register to serve as the lead plaintiff. ImmunityBio itself has only a few days remaining to formally respond to the FDA’s concerns.

A Dual Timeline for Shareholders

Moving forward, shareholders must monitor two critical deadlines. The legal front is dominated by the May 26 cutoff for structuring the class-action suit. Fundamentally, the focus shifts to the fourth quarter of 2026, when the planned submission of new clinical data to the FDA could represent the next major catalyst for Anktiva’s commercial expansion. The coming months will test the company’s ability to manage legal and regulatory headwinds while capitalizing on its strong clinical and commercial momentum.